Allergy Therapeutics Share Discussion Threads

[jpuff] 16/12/2022 19:49

Down the Swanny for yet another share I own. Cosmic!

[jimmyloser] 16/12/2022 09:25

Oh my days! Death by a thousand cuts!As you sow, so shall you reap!

[jimmyloser] 12/12/2022 17:38

I would say yes if they are of material value and would impact results.Impo

[genises] 12/12/2022 12:29

Does the company have to announce to the market if they have lost 3rd party contracts due to the sudden shut down. Open question

[jimmyloser] 09/12/2022 10:59

Not exactly a run for the door this morning.

[jpuff] 08/12/2022 20:49

In true style they'll get handsomely rewarded for screwing us over! It's always the way these days. There's no accountability even if you fail.

[red army] 08/12/2022 19:44

It would appear that the recent directors actions have beeb poor to say the least. Time to go me thinks.

[amishp67] 08/12/2022 18:45

I couldn't agree more. I believe that the wording regarding funding was slightly concerning. They have plenty of cash in the bank so why do they need to raise more money. Or are we mistaken because their wording is poor, and that because of the pause in production they are reviewing their working capital cycle to collect cash owed to them quicker..faster sales etc. I think they needed to be more clearer on what they mean exactly.It also makes you think why Directors are not snapping up shares at this price to show their confidence.That being said, I do think that we have to be patient here because if this is successful the share price will reverse and rocket up.There is a small percentage of retail investors in this company. Most are held by the big boys (who are clearly still holding) the volumes are small, it only takes small volumes to push this share price down, which to me means there's nothing to worry about. People who sell now will probably end up buying back once things progress.I think we good..just need to be patient (don't look at the price) and let's hope for promising progress on the grass and peanut.

[raleigh43] 08/12/2022 17:13

For me, this is all about the potential of the grass and peanut products. Progress is happening. If they do have a loss for next year, then they do. It happens to companies all the time as they prepare a switch to growth with new products.

The recent fundraising was from shareholders who know where the projects are at.

[genises] 08/12/2022 16:53

Thought we had done funding through Southern Fox and ZQ Capita{major shareholder}Who as a shareholder can not be happy with the share price.£7million at 20p
Nice to see the directors buying on the open market at these low prices not ,shows confidence.
Time for a New CEO.

[jimmyloser] 08/12/2022 16:22

overdone on nickel and dime trading impo

[jpuff] 08/12/2022 11:01

I think the RNS today was more a case of - This is what we have in the cupboard and where we're at followed by any funding agency or potential buyer of the company please come forward. I can't see a reversal of this apparent death spiral trend but hope I'm wrong as a LTH. We need something to reverse this trend asap

[jpuff] 08/12/2022 08:51

Let's hope not a fire sale or the 'we have failed to secure funding line' followed by the 'we can't guarantee a going concern' following that possibility!

[bspgamer] 08/12/2022 08:29

Have a look at EEE DYOR

[jimmyloser] 08/12/2022 08:27

jpuff
The contact Nick Wykeham bit intrigues me at the bottom. One can only hope that 'all options' including getting a buyer.........

[jpuff] 08/12/2022 08:20

The one year chart looks a complete horror story and what price will the funding option be at? !

[jimmyloser] 08/12/2022 08:18

Oh my days, time for a change.

DOWN.

[jpuff] 08/12/2022 08:18

The bit reviewing all funding options has me spooked

[jimmyloser] 08/12/2022 08:17

wizzkid, you are late.

[wizzkid211] 08/12/2022 08:16

Allergy Therapeutics Plc (LSE)
LSE:AGY



Allergy Therapeutics Share News (AGY)
4
Follow AGYBuySell
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
0.00 0.0% 13.25 13.00 13.50 0.00 19:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 84.3 3.7 0.5 29.4 85
Print
Alert
Allergy Therapeutics PLC Key updates on Grass MATA MPL and VLP Peanut
08/12/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Thursday 8 December 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 9931I

Allergy Therapeutics PLC

08 December 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics announces key updates on Grass MATA MPL

and VLP Peanut clinical programmes

Update on production and funding

- Innovative short-course grass pollen immunotherapy with best-in-class potential
- If successful, Grass MATA MPL will be the first subcutaneous and aluminium -- free short-course allergy immunotherapy approved in the US

- Topline safety & efficacy data for Grass MATA MPL expected Q4 2023
- Safety, tolerability and efficacy data for VLP peanut expected 2023
8 December 2022 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, t hat aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

Grass MATA MPL incorporates MicroCrystalline Tyrosine ("MCT(R) ") adsorbed allergoids, and the innovative adjuvant Monophosphoryl-lipid A ("MPL"). This innovative technology only requires patients to receive six injections prior to the grass allergy season to be protected.

The pivotal Phase III G306 trial is a multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to confirm the efficacy and safety of Grass MATA MPL. The clinical trial will be conducted in the US and Europe at approximately 120 clinical trial sites. Data readout is planned for Q4 2023.

Previously announced top-line results from the G309 exploratory field trial showed meaningful and statistically significant reductions in symptoms due to grass pollen allergy and in the use of relief medications after six SCIT injections with Grass MATA MPL during peak grass pollen season.

In addition, the first subjects have been screened and are poised to receive the Group's innovative, short-course peanut allergy vaccine candidate, VLP Peanut in the Phase I PROTECT trial. The first-in-human study is evaluating the safety and tolerability of VLP Peanut in healthy and peanut allergic adult subjects and exploring preliminary proof of efficacy. Plans remain on track for data in 2023.

Update on production and funding

Further to the announcement on the 28(th) October, work is continuing on cost control and tight capital management following the impact of the pause in production. This includes reviewing all funding options and managing the working capital of the Group.

Manuel Llobet, CEO of Allergy Therapeutics, commented: " The start of our pivotal Phase III G306 trial investigating the efficacy and safety of our Grass MATA MPL marks the culmination of our efforts to bring this innovative treatment to millions of patients affected by grass allergies in both the US and Europe. We were encouraged by the results of our short-course grass pollen immunotherapy in the highly successful G309 exploratory field trial and look forward to advancing the development of this innovative treatment. The start of the VLP Peanut PROTECT trial is a significant milestone and a testament to the hard work of the Allergy Therapeutics team, developing innovative approaches that have the potential to transform the way we treat and manage allergies."

More information about the Phase III G306 Grass MATA MPL trial can be found on ClinicalTrials.gov under the identifier NCT05540717 .

About Grass MATA MPL

Grass MATA MPL is being developed as a pre-seasonal subcutaneous immunotherapy product for the treatment of allergic rhinitis and/or rhinoconjunctivitis.

Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids that reduces the reactivity with immunoglobulin E (IgE) antibodies without a reduction in other important immunological properties, such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL), is included as an adjuvant to increase the immunogenic effect of the immunotherapy and to enhance the switch from an allergen specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like immune response.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -

[jpuff] 06/12/2022 08:36

Maybe a search for a buyer for the company afoot?

[jimmyloser] 06/12/2022 07:20

With the share price on its backside and their recent investments, along with their significant shareholding's, this mornings news should come as no surprise. For me it brings a glimmer of hope. Change afoot?Impo

[wizzkid211] 06/12/2022 07:05

Appointment of Non-Executive Directors

6 DECEMBER 2022: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents Southern Fox Investments Limited ("Southern Fox") and Simon represents ZQ Capital Management Limited ("ZQ Capital") acting through its affiliate SkyGem Acquisition Limited, both significant shareholders of the Company.

[pfmg] 02/12/2022 15:18

Don't see it getting bought out either. Patience has always been a big requirement here, that continues.